© 2002 European Society of Cardiology
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure
Institute of Internal Medicine, University of Siena Siena, Italy
* Corresponding author. Present address: Istituto di Semeiotica Medica, Ospedale Le Scotte, Viale Bracci, 53100 Siena, Italy; Tel.: +39-577-585451; fax: +39-577-44114. E-mail address: palazzuoli2{at}unisi.it
 |
Abstract |
|---|
Background: Recent studies have shown that carvedilol therapy in patients with heart failure improves clinical outcome and survival, however, the effects of such treatment on left cardiac morphology and function in elderly patients with severe heart failure has not been widely studied.
Aim: The purpose of this study was to establish the effect of carvedilol at short- and long-term on left ventricular size and performance with mono- and two-dimensional echocardiography, in subjects with dilated cardiomyopathy, NYHA III functional class, low LV ejection fraction (EF<35%) and mean age of >70 years.
Methods: We studied 48 patients, previously randomized to treatment with either carvedilol or placebo, and we performed echocardiographic evaluation at the start, and after 3 and 12 months. Left ventricular diameters, LV mass and fractional shortening were calculated by Deveraux formula; left ventricular volumes and ejection fraction were measured by area–length formula; pulmonary pressure was calculated by tricuspid reflow.
Results: After 3 months, only LV end-diastolic diameter was lower in the carvedilol group compared to the placebo group. Nevertheless, after 12 months, patients on carvedilol treatment showed a LV geometric and functional improvement compared to placebo. We found significant differences in: diastolic (P<0.01) and systolic diameters (P<0.001); on LV mass (P<0.002); on LV systolic volume (P<0.03); and on LV ejection fraction (P<0.01). Pulmonary pressure was also reduced in beta-blocker subjects (P<0.001).
Conclusions: Carvedilol therapy for 12 months reduced LV diameters and volumes. Thus, improving cardiac remodeling and LV systolic function in elderly patients with severe heart failure. Several months of therapy are required for these favorable effects to occur, as these changes do not occur in the short term.
Key Words: Carvedilol • Severe heart failure • Echocardiography • LV geometry
Received April 17, 2001; Revised July 4, 2001; Accepted March 20, 2002
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Hamdani, W. J. Paulus, L. van Heerebeek, A. Borbely, N. M. Boontje, M. J. Zuidwijk, J. G.F. Bronzwaer, W. S. Simonides, H. W. M. Niessen, G. J. M. Stienen, et al. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction Eur. Heart J., August 1, 2009; 30(15): 1863 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cioffi, L. Tarantini, S. De Feo, G. Pulignano, D. Del Sindaco, C. Stefenelli, and C. Opasich Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure Eur J Heart Fail, October 1, 2005; 7(6): 1040 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, D. Mortl, and R. Pacher Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey Eur J Heart Fail, June 1, 2005; 7(4): 657 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Waagstein, O. Stromblad, B. Andersson, M. Bohm, M. Darius, W. Delius, F. Goss, K.J. Osterziel, M. Sigmund, S.-P. Trenkwalder, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy Eur J Heart Fail, October 1, 2003; 5(5): 679 - 691. [Abstract] [Full Text] [PDF]
|
|